Oncology News | pharmaphorum

News

BMS, AbbVie get FDA OK for new myeloma regimen

Bristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they hope will help drive uptake of the drug.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J buys novel lung cancer drug from South Korea's Yuhan

Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC).

News

BMS and Infinity trial immunotherapy combo in bladder cancer

Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.

News

FDA green lights Pfizer's Lorbrena for aggressive lung cance...

Pfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer.

Views & Analysis

The Frauenkirche is a church in the Bavarian city of Munich that serves as the cathedral of the Archdiocese of Munich and Freising and seat of its Archbishop.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for

BMS, AbbVie get FDA OK for new myeloma regimen

J&J buys novel lung cancer drug from South Korea's Yuhan

BMS and Infinity trial immunotherapy combo in bladder cancer

FDA green lights Pfizer's Lorbrena for aggressive lung cance...

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks